Senesco Technologies, Inc. Opens New Clinical Trial Site at Seattle Cancer Care Alliance and is Treating the First West Coast Patient
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB:SNTID) reported the treatment of the first patient at the Company’s newly opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This patient is part of Senesco’s Phase 1b/2a clinical study of its therapeutic drug candidate, SNS01-T, targeting B-cell cancers.
Help employers find you! Check out all the jobs and post your resume.